ADVM - アバランシェ・バイオテクノロジ―ズ (Adverum Biotechnologies Inc.)

ADVMのニュース

   Why Earnings Season Could Be Great for Adverum (ADVM)  2020/03/11 13:46:00 Zacks Investment Research
Adverum (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
   Earnings Preview: Adverum Biotechnologies (ADVM) Q4 Earnings Expected to Decline  2020/02/26 17:30:38 Zacks Investment Research
Adverum Biotechnologies (ADVM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adverum Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm  2020/02/25 17:26:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $ADVM #ADVM--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adverum Biotechnologies, Inc.
   The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study  2020/02/20 12:06:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Arcus Biosciences Inc (NYSE: RCUS ) Ascendis Pharma A/S (NASDAQ: ASND ) AVITA MED LTD/S ADR (NASDAQ: RCEL )(reacted to its half-yearly results) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE )(said its therapeutic Immuno-STAT platform will be featured in a Merck & Co., Inc.'s (NYSE: MRK ) presentation at the Antigen Specific Immune Tolerance Drug Development Summit) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB )(reacted to its quarterly and full-year results) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc.
   Adverum Biotech Shares Move Higher On Positive Wet AMD Gene Therapy Data  2020/02/10 19:01:08 Benzinga
Adverum Biotechnologies Inc (NASDAQ: ADVM ) shares were trading higher Monday in reaction to a presentation of data from a Phase 1 study of its experimental gene therapy to treat wet age-related macular degeneration, or AMD. Efficacy, Safety Established Adverum said data from six patients in cohort two were treated with a single intravitreal injection of a threefold lower dose of ADVM-022 compared to the first cohort showed that the gene therapy demonstrated robust efficacy and evidence of a dose response. Four of the six patients in the second cohort remained rescue injection-free at 24 weeks at the low dose, while all six patients in the first cohort remained rescue injection-free at a median follow-up of 50 weeks, the company said. And for these patients, vision was generally maintained … Full story available on Benzinga.com
   Why Earnings Season Could Be Great for Adverum (ADVM)  2020/03/11 13:46:00 Zacks Investment Research
Adverum (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
   Earnings Preview: Adverum Biotechnologies (ADVM) Q4 Earnings Expected to Decline  2020/02/26 17:30:38 Zacks Investment Research
Adverum Biotechnologies (ADVM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adverum Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm  2020/02/25 17:26:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $ADVM #ADVM--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adverum Biotechnologies, Inc.
   The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study  2020/02/20 12:06:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Arcus Biosciences Inc (NYSE: RCUS ) Ascendis Pharma A/S (NASDAQ: ASND ) AVITA MED LTD/S ADR (NASDAQ: RCEL )(reacted to its half-yearly results) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE )(said its therapeutic Immuno-STAT platform will be featured in a Merck & Co., Inc.'s (NYSE: MRK ) presentation at the Antigen Specific Immune Tolerance Drug Development Summit) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB )(reacted to its quarterly and full-year results) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc.
   Adverum Biotech Shares Move Higher On Positive Wet AMD Gene Therapy Data  2020/02/10 19:01:08 Benzinga
Adverum Biotechnologies Inc (NASDAQ: ADVM ) shares were trading higher Monday in reaction to a presentation of data from a Phase 1 study of its experimental gene therapy to treat wet age-related macular degeneration, or AMD. Efficacy, Safety Established Adverum said data from six patients in cohort two were treated with a single intravitreal injection of a threefold lower dose of ADVM-022 compared to the first cohort showed that the gene therapy demonstrated robust efficacy and evidence of a dose response. Four of the six patients in the second cohort remained rescue injection-free at 24 weeks at the low dose, while all six patients in the first cohort remained rescue injection-free at a median follow-up of 50 weeks, the company said. And for these patients, vision was generally maintained … Full story available on Benzinga.com
   Stock Analysts’ Upgrades for November, 12th (ACAD, ADVM, AOBC, ATSG, BIDU, CLLS, DXPE, FEYE, FHB, FSBW)  2019/11/12 15:58:09 Modern Readers
Stock Analysts’ upgrades for Tuesday, November 12th: ACADIA Pharmaceuticals (NASDAQ:ACAD) was upgraded by analysts at BidaskClub from a sell rating to a hold rating. Adverum Biotechnologies (NASDAQ:ADVM) was upgraded by analysts at BidaskClub from a hold rating to a buy rating. American Outdoor Brands (NASDAQ:AOBC) was upgraded by analysts at BidaskClub from a buy rating […]
   Adverum Biotechnologies Enters Oversold Territory  2019/09/30 13:04:00 Zacks Investment Research
Adverum Biotechnologies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
   Adverum Biotechnologies (ADVM) Upgraded to Buy: Here's Why  2019/09/25 13:00:07 Zacks Investment Research
Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Adverum Reports Data From Phase I Wet AMD Study, Stock Down  2019/09/13 14:06:00 Zacks Investment Research
Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.
   Adverum Shares Sink After Phase 1 Readout From Wet AMD Gene Therapy Trial  2019/09/12 15:30:37 Benzinga
Adverum Biotechnologies Inc (NASDAQ: ADVM ) shares were plunging Thursday following the presentation of data from its gene therapy trial at a conference. What Happened Adverum, a gene therapy company focusing on ocular and rare diseases, announced 24-week, Phase 1 clinical data from the first cohort of patients treated with a one-time intravitreal dose of ADVM-022 for wet age-related macular degeneration, or wet AMD. The actively traded, small-cap biotech said the patients achieved vision maintenance and improvements in retinal anatomy after a one-time intravitreal dose of ADVM-022 through week 24. More importantly, … Full story available on Benzinga.com

calendar